Clinical Competition Candidate

VERDESO

Dermatology · Atopic dermatitis, mild–moderate (low-potency corticosteroid)

VERDESO carries product and use-code patents, low complexity (1/5), and meaningful clinical competition (5/5). The listed expiry window is approximately 13 months away. Active clinical competition may compress the generic entry window.

Back to watchlist Contact us about this drug

LOE window

13months

to latest listed patent expiry (August 13, 2027)

Expiry attractiveness: 4/5

Patent profile

Substance patent (none)

Product / formulation patent (listed)

Use-code patent (listed)

Patent count: 1

Complexity score: 1/5

Clinical competition

Score: 5/5

Active trials linked: 14

Phase 2/3 trials: 4

Higher scores indicate more trial activity for this ingredient — a proxy for competitive generic interest.

Drug overview

Active ingredient: DESONIDE

Applicant (NDA holder): GENUS LIFESCIENCES INC

Confidence: High

Market context

Therapeutic area: Dermatology

Indication: Atopic dermatitis, mild–moderate (low-potency corticosteroid)

U.S. market size (est.)< $100M

Estimated U.S. net sales tier. Verify current figures before commercial diligence.